Cesca Therapeutics (KOOL) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Cesca Therapeutics Reports Second Quarter Fiscal 2016 Results and Provides a Status Update to Investors
February 16, 2016 4:06 PM ESTRANCHO CORDOVA, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ: KOOL) (the Company), an autologous cell-based regenerative medicine company, today reported financial results for the second quarter of fiscal 2016 and provided an update to investors. The update included details of the closing of the previously announced $15 million strategic investment made in the Company by the Boyalife Group (Boyalife), a discussion of the scope of Boyalifes healthcare-related business interests and an update on the status of Cescas FDA approved Phase III pivotal trial for the treatment of no-option patients with critical limb ischemia... More
